Merck & Co. Inc. (NYSE: MRK) on Tuesday reported decrease gross sales and adjusted earnings for the second quarter of 2025. The corporate additionally introduced the acquisition of Verona Pharma plc.
Second-quarter gross sales have been $15.8 billion, in comparison with $16.1 billion within the prior yr quarter. Pharmaceutical gross sales declined by 2% whereas Animal Well being gross sales grew by 11%.
The corporate reported adjusted earnings of $2.13 per share for the second quarter, in comparison with $2.28 per share in Q2 2024. Reported internet earnings was $4.43 billion or $1.76 per share within the June quarter, in comparison with $5.46 billion or $2.14 per share in the identical interval of final yr.
Robert Davis, chief government officer of Merck, stated, “Immediately, we introduced a multiyear optimization initiative that can redirect funding and sources from extra mature areas of our enterprise to our burgeoning array of recent progress drivers, additional allow the transformation of our portfolio, and drive our subsequent chapter of productive, innovation-driven progress.”
Lately, Merck introduced the signing of an settlement to amass Verona Pharma plc for about $10 billion, below its science-led enterprise growth technique. Verona is a biopharma firm centered on growing and commercializing therapies for the remedy of power respiratory ailments.
